# Outset Medical Reports First-Quarter Results
Canonical URL: https://biopharmsignal.com/news/OM/outset-medical-reports-first-quarter-results
Ticker: OM
Company: Outset Medical
Source: Outset Medical
Published: 2026-05-07 20:02 EST
Original Source URL: https://investors.outsetmedical.com
## Summary

SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the first quarter ended March 31,

## Article Body
SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the first quarter ended March 31,
## Recent Company News
- 2026-05-11 20:05 EST — [Outset Medical to Present at RBC Global Healthcare Conference](https://biopharmsignal.com/news/OM/outset-medical-to-present-at-rbc-global-healthcare-conference) — Source: Outset Medical
- 2026-05-07 20:02 EST — [Outset Medical Reports First-Quarter Results](https://biopharmsignal.com/news/OM/outset-medical-reports-first-quarter-results) — Source: Outset Medical
- 2026-04-27 20:05 EST — [Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026](https://biopharmsignal.com/news/OM/outset-medical-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026) — Source: Outset Medical
- 2026-04-08 20:05 EST — [Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OM/outset-medical-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Outset Medical
- 2026-04-06 20:05 EST — [Outset Medical Names Derick Elliott as Executive Vice President of Commercial](https://biopharmsignal.com/news/OM/outset-medical-names-derick-elliott-as-executive-vice-president-of-commercial) — Source: Outset Medical
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)